🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Beijing Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Beijing Hospital as lead sponsor. Synced 26 Sep 2026
10Current trials
10Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Beijing Hospital is the lead sponsor of 10 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Insulin aspart and Telitacicept. The most-studied condition is Coronary Artery Disease.

ClinicalTrials.gov trials by status

  • Recruiting10100%

Trials by phase

  • Observational440%
  • Not applicable440%
  • Phase 2220%
01

Clinical trials sponsored by Beijing Hospital

10 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)
NCT06880575 · ClinicalTrials.gov ↗ · Coronary Arterial Disease (CAD), ELDERLY PEOPLE
Observational Recruiting 2024-11 China
Clinical Study on Dry Needling for Primary Dysmenorrhea and Its Preliminary Correlation With Acupoints
NCT06316583 · ClinicalTrials.gov ↗ · Trigger Point Pain, Myofascial, Acupuncture, Primary Dysmenorrhea
Not applicable Recruiting 2024-04 China
Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods
NCT06314295 · ClinicalTrials.gov ↗ · Coronary Artery Disease
Observational Recruiting 2024-03 China
Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
NCT05738980 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Not applicable Recruiting 2023-02 China
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
NCT06321081 · ClinicalTrials.gov ↗ · RAS Mutation, Metastatic Colorectal Cancer, MSS
Phase 2 Recruiting 2024-03 China
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
NCT05998759 · ClinicalTrials.gov ↗ · Connective Tissue Diseases, Thrombocytopenia
Phase 2 Recruiting 2023-12 China
5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease
NCT07781579 · ClinicalTrials.gov ↗ · Moyamoya Disease, Intracranial Hemorrhages, Stroke
Observational Recruiting 2026-02 China
Electroacupuncture Treatment for Discogenic Low Back Pain
NCT06703671 · ClinicalTrials.gov ↗ · Discogenic Low Back Pain
Not applicable Recruiting 2025-03 China
Identification for High Risk of Coronary Heart Disease Based on Quantitative Analysis of Fundus Vessels and Metabolic Molecules
NCT07773064 · ClinicalTrials.gov ↗ · Coronary Artery Disease
Observational Recruiting 2024-05 China
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
NCT03987308 · ClinicalTrials.gov ↗ · Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), T2DM
Not applicable Recruiting 2019-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Beijing Hospital trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Beijing Hospital trials

19 conditions
Coronary Artery Disease2Coronary Arterial Disease (CAD)1ELDERLY PEOPLE1Trigger Point Pain, Myofascial1Acupuncture1Primary Dysmenorrhea1Hepatocellular Carcinoma1RAS Mutation1Metastatic Colorectal Cancer1MSS1Connective Tissue Diseases1Thrombocytopenia1Moyamoya Disease1Intracranial Hemorrhages1Stroke1Discogenic Low Back Pain1Type 2 Diabetic Patients1T2DM (Type 2 Diabetes Mellitus)1T2DM1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1010

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Coronary Artery Disease

SponsorTrials
China National Center for Cardiovascular Diseases12
Nanjing First Hospital, Nanjing Medical University10
Second Affiliated Hospital, Zhejiang University, School of Medicine8
Shanghai Zhongshan Hospital7
Xijing Hospital6
Seung-Jung Park3
Second Hospital of Jilin University3
National University of Ireland, Galway, Ireland2
Philips Clinical & Medical Affairs Global2
Biosensors Europe2

Sponsors with the most current trials registered for this condition.

06

Questions about Beijing Hospital trials

How many clinical trials does Beijing Hospital sponsor?

Beijing Hospital is the lead sponsor of 10 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Beijing Hospital trials recruiting?

Yes. 10 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Beijing Hospital testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Insulin aspart (1) and Telitacicept (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.